<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00501943</url>
  </required_header>
  <id_info>
    <org_study_id>H9924-29155-05</org_study_id>
    <nct_id>NCT00501943</nct_id>
  </id_info>
  <brief_title>Neuroprotection With Riluzole Patients With Early Multiple Sclerosis</brief_title>
  <official_title>Neuroprotection With Riluzole in Patients With Early Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Multiple Sclerosis Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double blind, randomized, parallel group design placebo-controlled mono-center
      study. Patients will be evaluated within twelve months of CIS onset. Patients with at least 2
      silent ovoid T2 bright areas in the deep white matter on their clinic brain MRI scan will be
      offered participation in the study. Patients will be randomized to oral riluzole or placebo
      (1:1). Patient will take 50 mg of riluzole or placebo once a day for one month. If 50 mg once
      a day is well tolerated, patients will then go on 50 mg twice daily for the rest of the
      study. They will start Avonex (Interferon beta 1a) therapy 30 mcg IM once weekly 3 months
      after study drug (riluzole or placebo) is initiated if their liver function has remained
      normal.

      Forty patients within twelve months of onset CIS onset will be enrolled at UCSF MS Center.
      Patients will be evaluated every month for the first 12 months and every three months
      thereafter for a total study duration of 24-month. Enrollment period will last six months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine the effect of riluzole up to 50 mg bid on MRI parameters, including T1 lesions
      load, atrophy of gray and white matter, and 1H-MRSI; and to determine safety of riluzole when
      administered orally up to 50 mg bid for 2 years in double blinded clinical trial of patients
      with clinically isolated syndromes (CIS) and at least 2 silent T2-bright areas in the deep
      white matter. These patients have a high risk of conversion to MS within 2 years and faster
      rate of atrophy (Dalton 2004).

      Specific aims:

        1. To determine the effect of treatment compared to placebo on annual change in measures of
           normalized brain gray and white matter volume changes.

        2. To determine the effect of riluzole compared to placebo on annual change in proton
           spectroscopic intensities of N-acetyl aspartate (NAA) and glutamate in normal appearing
           white matter (NAWM), in acute and chronic lesions.

        3. To determine the safety of riluzole up to 50 mg bid in patients with CIS in association
           to Avonex (Interferon beta 1a) 30 mcg IM once a week.

        4. To monitor changes on MS functional composite (MSFC) (Cutter 1999, Rudick 1998), optic
           coherence tomography (OCT), low contrast sensitivity and EDSS in these patients.

        5. To monitor recovery from exacerbations.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MRI Parameter- Percent Brain Volume Change for 2 Years</measure>
    <time_frame>Baseline, Month-3, Month-6, Month-12, Month-18 and Month-24</time_frame>
    <description>Baseline MRI is compared to MRI images collected during subsequent timepoints. The percent brain volume change is measured using SIENAX (Structural Image Evaluation using Normalization of Atrophy-X)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Normalized White Matter Volumes (nWMV)</measure>
    <time_frame>Baseline, Month-3, Month-6, Month-12, Month-18 and Month-24</time_frame>
    <description>The baseline data of white matter volume obtained from the MRI images is compared to data obtained at time points using SIENA (Structural Image Evaluation using Normalization of Atrophy) and SIENAX</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in MS Functional Composite (MSFC)</measure>
    <time_frame>Baseline, Month-3, Month-6, Month-12, Month-18 and Month-24</time_frame>
    <description>Baseline MSFC data is compared to MSFC data collected during the timepoints. The MSFC is a three-part, standardized, quantitative, assessment instrument that measures the clinical dimensions of leg function, arm/hand function and cognitive function and the components include Timed 25-Foot walk, 9-Hole Peg Test and Paced Auditory Serial Addition Test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Peripapillary Retinal Nerve Fiber Layer Thickness (RNFL)</measure>
    <time_frame>Baseline, Month-3, Month-6, Month-12, Month-18 and Month-24</time_frame>
    <description>Baseline RNFL data is compared to the RNFL data collected during the timepoint, and the changes in RNFL is measured using optical coherence tomography (OCT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Symbol Digit Modality Test (SDMT)</measure>
    <time_frame>Baseline, Month-3, Month-6, Month-12, Month-18 and Month-24</time_frame>
    <description>Baseline SDMT data were compared to SDMT data collected during the timepoints. A simple substitution task, the SDMT gives the examinee 90 seconds to pair specific numbers with given geometric figures as a measure for screening cognitive impairment. The total score is the total number of correctly completed boxes in the time allowed. The test score range is from 0(worst outcome) to 110 (best outcome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Normalized Grey Matter Volume</measure>
    <time_frame>Baseline, Month-3, Month-6, Month-12 and Month-24</time_frame>
    <description>The baseline data of grey matter volume obtained from the MRI images is compared to data obtained at time points using SIENA (Structural Image Evaluation using Normalization of Atrophy) and SIENAX</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Riluzole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Riluzole + Avonex</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo + Avonex</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avonex (Interferon beta 1a)</intervention_name>
    <arm_group_label>Riluzole</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riluzole</intervention_name>
    <arm_group_label>Riluzole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient must give written informed consent;

          2. Patients with a early MS or clinically isolated syndromes (CIS) in the past 12 months
             as defined by an acute or sub-acute episode suggestive of demyelination affecting the
             optic nerves, brain stem or spinal cord or other central nervous system location.

          3. Entry age 18-55

          4. Males and females

          5. At least 2 silent T2 bright areas in the deep white matter on screening brain MRI.

          6. No riluzole, interferon, copaxone, cyclophosphamide, mitoxantrone or other off-label
             immunosuppressive drugs for MS prior to study entry

          7. No corticosteroid during the 4 weeks prior to baseline MRI exam

          8. No prior exposure to total lymphoid irradiation

          9. No history of substance abuse, including documented alcohol dependence within 6 months
             prior to screening or alcohol liver damage with AST , ALT &gt; twice upper normal limits

         10. No pregnant or nursing patients

         11. No history of systemic illness or medical condition that would limit the likelihood of
             completing the gadolinium-enhanced MRI procedures. Automatic exclusionary conditions
             will include hypersensitivity reaction to riluzole or any of the tablets components,
             uncontrolled hypertension, epilepsy, and insulin dependent diabetes, asthma, known
             malignancy other than skin cancer, symptomatic cardiac disease or metallic objects on
             or inside the body.

         12. Patients willing to use birth control during the study.

         13. Patients willing to go on Avonex therapy 3 months after being randomized to study drug
             and no contra-indication to use of interferon therapy.

        Exclusion Criteria:

          1. A history of major depression or psychosis.

          2. A clinically significant MS exacerbation within 30 days of the screening

          3. Pregnancy

          4. Abnormal screening liver function (AST or ALT &gt; twice the upper normal limit).

          5. Patients receiving hepatotoxic medications such as drugs interfering with CYP 1A2.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emmanuelle Waubant, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSF , MS Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emmanuelle Waubant, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSF, MS Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF MS Center , 675 Nelson Rising Lane, Suite 221</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2007</study_first_submitted>
  <study_first_submitted_qc>July 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2007</study_first_posted>
  <results_first_submitted>November 19, 2013</results_first_submitted>
  <results_first_submitted_qc>March 11, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 9, 2014</results_first_posted>
  <last_update_submitted>March 11, 2014</last_update_submitted>
  <last_update_submitted_qc>March 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Emmanuelle Waubant</investigator_full_name>
    <investigator_title>Associate Professor of Clinical Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Interferon beta-1a</mesh_term>
    <mesh_term>Riluzole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients with diagnosis of early Relapsing Remitting MS were invited to participate in the study at 2 US sites- UCSF and OHSU during the period between Dec 2007 and May 2010</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Riluzole</title>
          <description>Riluzole
Riluzole 50 mg BID added to weekly injection of Interferon beta 1a</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>placebo
1 tab of Placebo BID added to weekly injection of Interferon beta 1a</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Riluzole</title>
          <description>Riluzole
Riluzole 50 mg BID added to weekly injection of Interferon beta 1a</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>placebo
1 tab of Placebo BID added to weekly injection of Interferon beta 1a</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.2" spread="9.84"/>
                    <measurement group_id="B2" value="32.4" spread="7.85"/>
                    <measurement group_id="B3" value="36" spread="9.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>percent</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>MRI Parameter- Percent Brain Volume Change for 2 Years</title>
        <description>Baseline MRI is compared to MRI images collected during subsequent timepoints. The percent brain volume change is measured using SIENAX (Structural Image Evaluation using Normalization of Atrophy-X)</description>
        <time_frame>Baseline, Month-3, Month-6, Month-12, Month-18 and Month-24</time_frame>
        <population>Multivariate regression model was used as the statistical method of analysis for the study. So data from patients who have not completed the study are also used for statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Riluzole</title>
            <description>Riluzole
Riluzole 50 mg BID added to weekly injection of Interferon beta 1a</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo
1 tab of Placebo BID added to weekly injection of Interferon beta 1a</description>
          </group>
        </group_list>
        <measure>
          <title>MRI Parameter- Percent Brain Volume Change for 2 Years</title>
          <description>Baseline MRI is compared to MRI images collected during subsequent timepoints. The percent brain volume change is measured using SIENAX (Structural Image Evaluation using Normalization of Atrophy-X)</description>
          <population>Multivariate regression model was used as the statistical method of analysis for the study. So data from patients who have not completed the study are also used for statistical analysis.</population>
          <units>percent change per year</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.862" lower_limit="-1.168" upper_limit="-0.556"/>
                    <measurement group_id="O2" value="-0.49" lower_limit="-0.766" upper_limit="-0.208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Normalized White Matter Volumes (nWMV)</title>
        <description>The baseline data of white matter volume obtained from the MRI images is compared to data obtained at time points using SIENA (Structural Image Evaluation using Normalization of Atrophy) and SIENAX</description>
        <time_frame>Baseline, Month-3, Month-6, Month-12, Month-18 and Month-24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Riluzole</title>
            <description>Riluzole
Riluzole or Placebo, and Avonex(Interferon beta 1a): Riluzole, Placebo and Avonex(Interferon beta 1a)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo
Riluzole or Placebo, and Avonex(Interferon beta 1a): Riluzole, Placebo and Avonex(Interferon beta 1a)</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Normalized White Matter Volumes (nWMV)</title>
          <description>The baseline data of white matter volume obtained from the MRI images is compared to data obtained at time points using SIENA (Structural Image Evaluation using Normalization of Atrophy) and SIENAX</description>
          <units>percent change per year</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.75" lower_limit="-14.709" upper_limit="11.213"/>
                    <measurement group_id="O2" value="-9.69" lower_limit="-22.206" upper_limit="2.825"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in MS Functional Composite (MSFC)</title>
        <description>Baseline MSFC data is compared to MSFC data collected during the timepoints. The MSFC is a three-part, standardized, quantitative, assessment instrument that measures the clinical dimensions of leg function, arm/hand function and cognitive function and the components include Timed 25-Foot walk, 9-Hole Peg Test and Paced Auditory Serial Addition Test.</description>
        <time_frame>Baseline, Month-3, Month-6, Month-12, Month-18 and Month-24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Riluzole</title>
            <description>Riluzole
Riluzole or Placebo, and Avonex(Interferon beta 1a): Riluzole, Placebo and Avonex(Interferon beta 1a)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo
Riluzole or Placebo, and Avonex(Interferon beta 1a): Riluzole, Placebo and Avonex(Interferon beta 1a)</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in MS Functional Composite (MSFC)</title>
          <description>Baseline MSFC data is compared to MSFC data collected during the timepoints. The MSFC is a three-part, standardized, quantitative, assessment instrument that measures the clinical dimensions of leg function, arm/hand function and cognitive function and the components include Timed 25-Foot walk, 9-Hole Peg Test and Paced Auditory Serial Addition Test.</description>
          <units>percent change per year</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.041" lower_limit="-0.043" upper_limit="0.126"/>
                    <measurement group_id="O2" value="0.052" lower_limit="-0.030" upper_limit="0.133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Peripapillary Retinal Nerve Fiber Layer Thickness (RNFL)</title>
        <description>Baseline RNFL data is compared to the RNFL data collected during the timepoint, and the changes in RNFL is measured using optical coherence tomography (OCT).</description>
        <time_frame>Baseline, Month-3, Month-6, Month-12, Month-18 and Month-24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Riluzole</title>
            <description>Riluzole
Riluzole or Placebo, and Avonex(Interferon beta 1a): Riluzole, Placebo and Avonex(Interferon beta 1a)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo
Riluzole or Placebo, and Avonex(Interferon beta 1a): Riluzole, Placebo and Avonex(Interferon beta 1a)</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Peripapillary Retinal Nerve Fiber Layer Thickness (RNFL)</title>
          <description>Baseline RNFL data is compared to the RNFL data collected during the timepoint, and the changes in RNFL is measured using optical coherence tomography (OCT).</description>
          <units>percent change per year</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.670" lower_limit="-9.309" upper_limit="-0.032"/>
                    <measurement group_id="O2" value="-1.839" lower_limit="-6.692" upper_limit="3.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Symbol Digit Modality Test (SDMT)</title>
        <description>Baseline SDMT data were compared to SDMT data collected during the timepoints. A simple substitution task, the SDMT gives the examinee 90 seconds to pair specific numbers with given geometric figures as a measure for screening cognitive impairment. The total score is the total number of correctly completed boxes in the time allowed. The test score range is from 0(worst outcome) to 110 (best outcome).</description>
        <time_frame>Baseline, Month-3, Month-6, Month-12, Month-18 and Month-24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Riluzole</title>
            <description>Riluzole
Riluzole or Placebo, and Avonex(Interferon beta 1a): Riluzole, Placebo and Avonex(Interferon beta 1a)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo
Riluzole or Placebo, and Avonex(Interferon beta 1a): Riluzole, Placebo and Avonex(Interferon beta 1a)</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Symbol Digit Modality Test (SDMT)</title>
          <description>Baseline SDMT data were compared to SDMT data collected during the timepoints. A simple substitution task, the SDMT gives the examinee 90 seconds to pair specific numbers with given geometric figures as a measure for screening cognitive impairment. The total score is the total number of correctly completed boxes in the time allowed. The test score range is from 0(worst outcome) to 110 (best outcome).</description>
          <units>percent change per year</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.342" lower_limit="-0.774" upper_limit="1.457"/>
                    <measurement group_id="O2" value="0.417" lower_limit="-0.703" upper_limit="1.537"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Normalized Grey Matter Volume</title>
        <description>The baseline data of grey matter volume obtained from the MRI images is compared to data obtained at time points using SIENA (Structural Image Evaluation using Normalization of Atrophy) and SIENAX</description>
        <time_frame>Baseline, Month-3, Month-6, Month-12 and Month-24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Riluzole</title>
            <description>Riluzole
Riluzole or Placebo, and Avonex(Interferon beta 1a): Riluzole, Placebo and Avonex(Interferon beta 1a)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo
Riluzole or Placebo, and Avonex(Interferon beta 1a): Riluzole, Placebo and Avonex(Interferon beta 1a)</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Normalized Grey Matter Volume</title>
          <description>The baseline data of grey matter volume obtained from the MRI images is compared to data obtained at time points using SIENA (Structural Image Evaluation using Normalization of Atrophy) and SIENAX</description>
          <units>percent change per year</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.369" lower_limit="-30.566" upper_limit="1.827"/>
                    <measurement group_id="O2" value="-18.444" lower_limit="-34.434" upper_limit="-2.454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From screening to Month-24 / withdrawal visit.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Riluzole</title>
          <description>Riluzole
Riluzole 50 mg BID added to weekly injection of Interferon beta 1a</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>placebo
1 tab of Placebo BID added to weekly injection of Interferon beta 1a</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="22"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated liver function tests</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Emmanuelle Waubant, MD</name_or_title>
      <organization>UCSF</organization>
      <phone>415- 514 2468</phone>
      <email>Emmanuelle.Waubant@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

